- General Information
- Scientific Posters
- Industry Involvement
- Useful Links
- Congress Archive
- HIV & Hepatitis in the Americas
- HIV Research Trust
The programme detail of the sessions below is available by clicking here
Sunday 23 October
10.30-11.30 AbbVie Industry Workshop
14.30-16.00 Janssen Industry Symposium
Monday 24 October
17.30-19.00 Gilead Sciences Europe Ltd Industry Symposium
Tuesday 25 October
08.30-10.00 Merck Sharp & Dohme Industry Symposium
17.30-19.00 ViiV Healthcare Industry Symposium
About Gilead Sciences
Gilead Sciences, a research-based biopharmaceutical company, discovers, develops and commercialises innovative medicines in areas of unmet medical need. Gilead’s therapeutic areas of focus include HIV/AIDS, liver diseases, haematology and oncology inflammatory and respiratory diseases and cardiovascular conditions. Founded in 1987 in Foster City, California, Gilead now employs approximately 8,300 people in offices across six continents. Gilead has become a leading biopharmaceutical company with a rapidly expanding product portfolio and a growing pipeline of investigational drugs. Millions of people around the world are living healthier, more fulfilling lives because of innovative therapies developed by Gilead. For more information, please visit www.gilead.com.
About Janssen Pharmaceutical Companies
At Janssen Pharmaceutical Companies of Johnson & Johnson we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We work to bring together the best minds and pursue the most promising science as well as collaborate with the world for the health of everyone in it.
We stand united with the global community to make an HIV-free world a reality. Building on our 25 year legacy of commitment to end HIV, our goal is to help ensure that every baby is born HIV-free, adolescents and adults stay HIV-free and people living with HIV have access to the medicines they need. As part of these efforts to curb the HIV/AIDS epidemic, we have developed six transformational HIV medicines, including INTELENCE®, PREZISTA®, EDURANT®, EVIPLERA®, ODEFSEY® and REZOLSTA®. We are working with partners around the world to advance R&D of several innovative preventive methods, including an HIV vaccine, which remains a top global health priority.
By utilising our resources and expertise, together we can make HIV history. Learn more at http://www.janssen.com/emea/.
About Merck Sharp & Dohme
HIV represents one of the greatest health challenges facing the world today. For more than 25 years, MSD has been at the forefront of the global response to the HIV epidemic through a three-pronged approach:
1. Working to discover, develop and deliver breakthrough medicines to address both treatment and prevention.
2. Developing an approach to help our products reach as many people as possible.
3. Participating in partnerships with governments, multilateral organizations, community-based organizations, other corporations and non-governmental organizations to help build infrastructure and address health and development challenges around the world.
Through these and other pioneering efforts, MSD is making a substantial contribution toward meeting one of the most critical needs targeted by the United Nations Millennium Development Goals: halting and beginning to reverse the spread of HIV. For more information, visit www.msd.com.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.